# Granisetron Transdermal Patch System for Prevention of CINV by CapeOX

> **NCT05325190** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 57 (estimated)

## Conditions studied

- Chemotherapy-induced Nausea and Vomiting

## Interventions

- **DRUG:** Granisetron Transdermal Patch System

## Key facts

- **NCT ID:** NCT05325190
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-10
- **Primary completion:** 2022-12-30
- **Final completion:** 2023-06-01
- **Target enrollment:** 57 (ESTIMATED)
- **Last updated:** 2022-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05325190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05325190, "Granisetron Transdermal Patch System for Prevention of CINV by CapeOX". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05325190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*